Efficacy and safety evaluation of a lead gene therapy candidate in methyl melanomic acidemia (mmab) disease mouse models and bioanalytical assay methods development.
Ended Awarded Last action
- Contract number
- 75N95021F00002
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $452,931
Award facts
- Opportunity
-
- 75N95021R00046 Solicitation number
- Contract value 100% obligated
- $452,930.99 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $86,008 | |
| Terminate for Convenience | -$256,960 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $623,883 |
About this award
The National Institute on Drug Abuse issued a delivery order to Lovelace Biomedical Research Institute on September 29, 2021, with a ceiling value of $452,930.99 for efficacy and safety evaluation of a lead gene therapy candidate in methyl melanomic acidemia disease mouse models and bioanalytical assay methods development.
Place of performance is Albuquerque, NM. The order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of May 31, 2026. No set-aside was used.
Service Contract Inventory reporting shows minimal recent labor activity. In FY2022, the order invoiced $563 across 5 contractor hours at a derived rate of $125.28 per hour. In FY2024, 2 contractor hours were reported at zero invoiced dollars. Lovelace self-performed all reported hours with no subcontractors engaged.
Quick answers
Who was awarded contract 75N95021F00002?
75N95021F00002 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 29, 2021.
How much is contract 75N95021F00002 worth?
The government has obligated $452,931 on 75N95021F00002.
Is contract 75N95021F00002 an order under another contract?
Yes. 75N95021F00002 is a delivery order under 75N95019D00012, an indefinite delivery contract.
Was contract 75N95021F00002 competed?
The extent of competition for 75N95021F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award